The MEL@308nm laser – State-of-the-art in phototherapy
for the treatment of psoriasis and vitiligo
Experimentation has demonstrated the efficacy of DEKA’s MEL@308nm light sources for the clinical symptoms of psoriasis on elbows, knees, back, soles of the feet, and palms of the hand, generating prolonged remission of the disease and considerably enhancing the patient’s quality of life. Trials on vitiligo have demonstrated cases with an acceptable to excellent degree of re-pigmentation on the face, neck, back, abdomen, and limbs.
How it Works
Molecular biology and immunohistochemical (IHC) studies have demonstrated how irradiation of the skin with MEL@308nm causes a precocious reduction of the T-lymphocytes of the infiltrate at both an epidermal and dermal level within 24 to 48 hours, even after only one session. This suggests that the MEL@308nm light source has a direct effect on the cellular infiltrate, demonstrated by the drastic decrease in the expression of inflammatory cytokines involved in the pathogenetic mechanism of psoriasis (IL-6, IL-8, TGF-α, TNF-α and INF-γ).
After treatment, a rapid increase in the expression of the mediatric proteins of the apoptotic process (p53) is recorded, combined with a reduced expression of the anti-apoptotic proteins (Bcl-2) and the cellular proliferation process (Ki-67).
Even after just one treatment, the thickening of the nuclear chromatin of the epidermal layers is the earliest sign of the beginning of the apoptotic process, and clearly indicates that the route followed by the epidermis and the infiltrate towards healing is that of programmed cell death.